Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RabTarget4Metastasis

Financiado

Cerrado

Targeting Rab27A with covalent inhibitors for the treatment of metastatic breast...

Targeting Rab27A with covalent inhibitors for the treatment of metastatic breast cancer Invasion and metastases remain to date the major causes of cancer mortality around the world. Rab27A is a small GTPase that regulates vesicles trafficking and is involved in many physiological processes, e.g. melanosome transport.... ver más

29/10/2022

IMPERIAL COLLEGE O...

225K€

Presupuesto del proyecto: 225K€

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-10-29

MSCA-IF-2019: Individual Fellowships

I+D

Cerrada hace 5 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

IMPERIAL COLLEGE OF SCIENCE...

224.93K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2013-48657-R MODULACION DE LA PROGRESION TUMORAL POR ENZIMAS PI3K: APROXI... 484K€ Cerrado

BIO2016-78006-R EL ELEMENTO REGULADOR N-TERMINAL DE SRC: METODOS Y ESTRATEGI... 272K€ Cerrado

PDC2022-133807-I00 PEQUEÑAS MOLECULAS MODULADORAS DE LA ACTIVIDAD DE RB PARA EL... 150K€ Cerrado

PRENCTUM Protein tyrosine phosphatases as regulators of N cadherin me... 209K€ Cerrado

MRCKa in cancer Targeting Cancer Cell Invasion and Metastasis by Inhibition... 200K€ Cerrado

MICROENVIMET Understanding and fighting metastasis by modulating the tumo... 4M€ Cerrado

Duración del proyecto: 31 meses Fecha Inicio: 2020-03-13
Fecha Fin: 2022-10-29

Líder del proyecto

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND ME... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 225K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Invasion and metastases remain to date the major causes of cancer mortality around the world. Rab27A is a small GTPase that regulates vesicles trafficking and is involved in many physiological processes, e.g. melanosome transport. Being a small GTPase, Rab27A acts as a molecular switch that cycles between an inactive state (GDP bound) and an active state (GTP bound), in which this protein is able to bind to specific effectors to trigger signalling cascades in cells. Current studies suggest a role for Rab27A in exosome-mediated pre-metastatic niche promotion. Hence, interfering with Rab27A PPIs could be effective in reducing and preventing the occurrence of metastasis in cancer. Small GTPases are renowned as challenging targets and have been long considered undruggable, but the unique presence of two non-conserved cysteines in Rab27A offers a perfect starting point for the development of selective covalent inhibitors. These residues are located in the proximity of a major interaction site with a known effector of Rab27A, Slp2, therefore encouraging for targeting PPIs. A screen of covalent fragments based on the recently developed quantitative Irreversible Tethering (qIT) assay has led to the discovery of novel hits with enhanced reactivity for Rab27A against glutathione. The current project aims to (i) obtain potent Rab27A covalent inhibitors by growing hit fragments, and (ii) demonstrate selective Rab27A target engagement in cells, and efficient disruption of the PPIs of Rab27A with its main effectors. Collaboration with the CRUK Beatson Institute will provide direct access to in vivo models to validate the contribution of Rab27A to metastatic development in cancer by use of such chemical probes, whilst state-of-the-art covalent fragment know-how will be accessed for compound optimisation at the Francis Crick Institute/GSK LinkLab, enabling prompt evaluation of the therapeutic potential of optimised lead compounds that will derive from my work.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores